comparemela.com

Latest Breaking News On - சிற்றலை சிகிச்சை நிறுவனம் - Page 1 : comparemela.com

Ripple Therapeutics Research on Polymer-Free Drug Delivery Published in Nature Communications

Ripple Therapeutics Research on Polymer-Free Drug Delivery Published in Nature Communications Polymer-Free Corticosteroid Dimer Implants for Controlled and Sustained Drug Delivery was recently published in Nature Communications. The article describes Ripple s Epidel technology platform which is founded on a discovery that drugs can be engineered into drug delivery implants without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. implantable cylinders, micro/nanoparticles, etc.) or as coatings for medical devices without a polymeric carrier. Ripple Therapeutics implants and coatings are made up entirely from the prodrug so when the drug is gone the implant is gone. The implants and coatings undergo surface erosion achieving tightly controlled and reproducible release kinetics. Drug release profiles are highly engineerable (e.g. differe

Ripple Therapeutics Appoints Jonathan Talamo, M D , to Board of Directors

Ripple Therapeutics Appoints Jonathan Talamo, M.D., to Board of Directors ACCESSWIRE 04 May 2021, 22:05 GMT+10 TORONTO, ON / ACCESSWIRE / May 4, 2021 / Ripple Therapeutics Corporation ( Ripple ) a clinical stage, ophthalmology-focused developer of novel pharmaceuticals, is pleased to announce the appointment of Jonathan Talamo, M.D., to the Board of Directors. Dr. Talamo is internationally known as an ophthalmologist, innovator and consultant to industry with more than 25 years of experience in healthcare. Dr. Talamo is the former Chief Medical Officer and Worldwide VP of Clinical and Medical Affairs at Johnson and Johnson Vision. Prior to that, he served as the Chief Medical Officer at Ocular Therapeutix, an ophthalmic drug delivery company, where he oversaw clinical development programs in multiple therapeutic areas, including post-cataract surgery inflammation, dry eye, allergy, glaucoma and retinal vascular diseases.

Ripple Therapeutics Announces First Patient Treated in Phase II Trial Evaluating IBE-814 IVT in DME and RVO

Ripple Therapeutics Announces First Patient Treated in Phase II Trial Evaluating IBE-814 IVT in DME and RVO
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Théa Open Innovation

Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Théa Open Innovation TORONTO, ON / ACCESSWIRE / December 15, 2020 / Ripple Therapeutics Corporation ( Ripple or the Company ), a clinical stage, ophthalmology-focused developer of novel therapeutics, announced today the signing of an exclusive Licensing Agreement for the rights to their lead product, IBE-814, for North America and Europe with Théa Open Innovation ( TOI ) a wholly owned subsidiary of Laboratoires Théa, the leading independent ophthalmology pharmaceutical company in Europe. In addition to the Licensing Agreement, Ripple announced that TOI is leading their Series A Financing. Ripple s Epidel ® technology platform is founded on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. The proprietary prodrugs have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.